Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab

Recently, concern has been raised about the influence of the previous disease-modifying treatments (DMTs) on the clinical efficacy of ocrelizumab (OCR).We aimed to evaluate whether the previous DMT affects the lymphocyte subset kinetics in people with Multiple Sclerosis (MS) switching to OCR.

Source: Journal of Neuroimmunology - March 25, 2023 Category: Allergy & Immunology Authors: Gianmarco Abbadessa, Giuseppina Miele, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Marco Vercellino, Antonio De Martino, Vittorio Simeon, Luigi Lavorgna, Simona Bonavita Source Type: research